Elevated serum levels of HIF-1α and VEGF as potential biomarkers in connective tissue disease-associated pulmonary arterial hypertension

Abstract We to measure the serum levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in patients diagnosed with connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH) (CTD-PAH) and to analyze their clinical implications. Thirty patients who were diagnosed with CTD-PAH via right heart catheterization (RHC) were enrolled in the observation group. Additionally, twenty CTD patients without PAH (CTD-non-PAH) were enrolled in the CTD-non-PAH group, and twenty healthy participants were enrolled in the healthy control group. Additional data on CTD-PAH patients, including demographic characteristics, laboratory parameters, and hemodynamic measurements, were obtained. The serum levels of HIF-1α and VEGF in all participants were measured using an enzyme-linked immunosorbent assay (ELISA). Pearson correlation was utilized to determine the correlation between the expression levels of these factors and clinical data. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to evaluate the diagnostic efficacy of expression of HIF-1α and VEGF for diagnosing CTD-PAH. Participants in the three groups were age-matched. The CTD-PAH group included 29 females and 1 male, and systemic lupus erythematosus (SLE) was the most prevalent CTD diagnosis (17/30). Serum levels of VEGF and HIF-1α were significantly greater in both CTD-PAH and CTD-non-PAH patients compared to the healthy controls (P